Similar articles for PMID: 19273529

Year	Number of Results
2000	2
2003	3
2004	6
2005	4
2006	1
2007	6
2008	4
2009	19
2010	17
2011	13
2012	26
2013	20
2014	8
2015	8
2016	4
2017	2
2018	5
2019	5
2020	6
2021	6
2022	16
2023	5
2024	0

1

Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier.

Zhao R, Raub TJ, Sawada GA, Kasper SC, Bacon JA, Bridges AS, Pollack GM. Zhao R, et al. Drug Metab Dispos. 2009 Jun;37(6):1251-8. doi: 10.1124/dmd.108.025064. Epub 2009 Mar 9. Drug Metab Dispos. 2009. PMID: 19273529 Free PMC article.

2

(R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.

Römermann K, Wanek T, Bankstahl M, Bankstahl JP, Fedrowitz M, Müller M, Löscher W, Kuntner C, Langer O. Römermann K, et al. Nucl Med Biol. 2013 Oct;40(7):873-8. doi: 10.1016/j.nucmedbio.2013.05.012. Epub 2013 Jul 8. Nucl Med Biol. 2013. PMID: 23845421 Free PMC article.

3

Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.

Kodaira H, Kusuhara H, Ushiki J, Fuse E, Sugiyama Y. Kodaira H, et al. J Pharmacol Exp Ther. 2010 Jun;333(3):788-96. doi: 10.1124/jpet.109.162321. Epub 2010 Mar 19. J Pharmacol Exp Ther. 2010. PMID: 20304939

4

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.

Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH. Marchetti S, et al. Mol Cancer Ther. 2008 Aug;7(8):2280-7. doi: 10.1158/1535-7163.MCT-07-2250. Mol Cancer Ther. 2008. PMID: 18723475

5

Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.

Minocha M, Khurana V, Qin B, Pal D, Mitra AK. Minocha M, et al. Int J Pharm. 2012 Sep 15;434(1-2):306-14. doi: 10.1016/j.ijpharm.2012.05.028. Epub 2012 May 23. Int J Pharm. 2012. PMID: 22633931 Free PMC article.

6

P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.

Yang JJ, Milton MN, Yu S, Liao M, Liu N, Wu JT, Gan L, Balani SK, Lee FW, Prakash S, Xia CQ. Yang JJ, et al. Drug Metab Lett. 2010 Dec;4(4):201-12. doi: 10.2174/187231210792928279. Drug Metab Lett. 2010. PMID: 20670210

7

Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.

Kodaira H, Kusuhara H, Fujita T, Ushiki J, Fuse E, Sugiyama Y. Kodaira H, et al. J Pharmacol Exp Ther. 2011 Dec;339(3):935-44. doi: 10.1124/jpet.111.180398. Epub 2011 Sep 20. J Pharmacol Exp Ther. 2011. PMID: 21934030

8

In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.

Marchetti S, Oostendorp RL, Pluim D, van Eijndhoven M, van Tellingen O, Schinkel AH, Versace R, Beijnen JH, Mazzanti R, Schellens JH. Marchetti S, et al. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3307-13. doi: 10.1158/1535-7163.MCT-07-0461. Mol Cancer Ther. 2007. PMID: 18089724

9

P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.

Durmus S, Xu N, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Durmus S, et al. Pharmacol Res. 2013 Oct;76:9-16. doi: 10.1016/j.phrs.2013.06.009. Epub 2013 Jul 1. Pharmacol Res. 2013. PMID: 23827160

10

Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.

Lee YJ, Kusuhara H, Jonker JW, Schinkel AH, Sugiyama Y. Lee YJ, et al. J Pharmacol Exp Ther. 2005 Jan;312(1):44-52. doi: 10.1124/jpet.104.073320. Epub 2004 Sep 24. J Pharmacol Exp Ther. 2005. PMID: 15448171

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

162 results

Results by year